Transparency
A transparent approach to our collaboration with Healthcare Professionals and Healthcare Organisations.
Disclosure of Transfers of Value
At Johnson & Johnson, we are committed to transparency in our collaboration with Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs). These partnerships are essential in advancing healthcare and improving patient outcomes, and we believe that transparency is key to fostering trust and ensuring ethical collaboration.
We work closely with HCPs and HCOs in various capacities, whether inviting them to share their expertise at medical education events or providing consultation to enhance patient care. In some cases, Transfers of Value (ToV) occur, where HCPs and HCOs are compensated for their contributions, such as speaking at conferences, providing advisory services, or attending medical congresses. These transfers may include covering registration fees, reasonable travel, or accommodation costs. Additionally, we support educational programmes that further healthcare professionals’ development.
Why Do We Disclose Transfers of Value?
As part of our commitment to responsible and transparent business practices, Johnson & Johnson complies with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on Disclosure of Transfers of Value, adopted in June 2013. This code ensures that pharmaceutical companies openly disclose any financial interactions with HCPs and HCOs, reinforcing the integrity of these relationships.
Our Disclosure Practices in Ireland
In Ireland, we follow the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice, which requires the disclosure of all Transfers of Value. Johnson & Johnson publishes this information annually, with full details available on the IPHA website: www.transferofvalue.ie
.
Since June 2016, we have been reporting Transfers of Value for the preceding calendar year. Johnson & Johnson fully supports this disclosure, as we believe that openness about financial interactions between pharmaceutical companies and the healthcare community enhances trust and underscores the legitimacy of these collaborations.
At Johnson & Johnson, transparency isn’t just a requirement—it’s a value we uphold to ensure that our collaborations with HCPs and HCOs are conducted with the highest standards of integrity. By disclosing Transfers of Value, we continue to build on our strong foundation of trust within the healthcare community, ensuring that these collaborations remain focused on improving patient outcomes and advancing healthcare for all.
We work closely with HCPs and HCOs in various capacities, whether inviting them to share their expertise at medical education events or providing consultation to enhance patient care. In some cases, Transfers of Value (ToV) occur, where HCPs and HCOs are compensated for their contributions, such as speaking at conferences, providing advisory services, or attending medical congresses. These transfers may include covering registration fees, reasonable travel, or accommodation costs. Additionally, we support educational programmes that further healthcare professionals’ development.
Why Do We Disclose Transfers of Value?
As part of our commitment to responsible and transparent business practices, Johnson & Johnson complies with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on Disclosure of Transfers of Value, adopted in June 2013. This code ensures that pharmaceutical companies openly disclose any financial interactions with HCPs and HCOs, reinforcing the integrity of these relationships.
Our Disclosure Practices in Ireland
In Ireland, we follow the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice, which requires the disclosure of all Transfers of Value. Johnson & Johnson publishes this information annually, with full details available on the IPHA website: www.transferofvalue.ie
You are now leaving J&J Innovative Medicine Ireland
The site you’re being redirected to is an external website where this Privacy Policy does not apply. Please click below to continue to that site.
Since June 2016, we have been reporting Transfers of Value for the preceding calendar year. Johnson & Johnson fully supports this disclosure, as we believe that openness about financial interactions between pharmaceutical companies and the healthcare community enhances trust and underscores the legitimacy of these collaborations.
At Johnson & Johnson, transparency isn’t just a requirement—it’s a value we uphold to ensure that our collaborations with HCPs and HCOs are conducted with the highest standards of integrity. By disclosing Transfers of Value, we continue to build on our strong foundation of trust within the healthcare community, ensuring that these collaborations remain focused on improving patient outcomes and advancing healthcare for all.